David Hepworth, Ph.D. is VP of Medicinal Chemistry at Pfizer’s Cambridge MA site responsible for Inflammation and Immunology, Rare Diseases and Chemical Biology. Previously he has worked across a number of other disease areas and Pfizer sites. He has a long-standing interest in membrane proteins and SLC transporters in particular, having worked in the area since his first Pfizer project in 1999 focusing on the serotonin transporter, through the initiation of Pfizer’s SGLT2 program for diabetes treatment. David has co-led, together with Dr Claire Steppan, a Pfizer team building research capabilities in SLC transporters which led to Pfizer taking a leading role in the RESOLUTE consortium.